

18-017-S-037



NDA 18-017/S-037

Merck & Co., Inc.
Attention: Mr. Kenneth A. Kramer
Sumney Town Pike
P.O. Box 4, BLA-20
West Point, PA 19486

Dear : Mr. Kramer:

Please refer to your supplemental new drug application dated September 19, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Blocadren (timolol maleate) 5, 10 and 20 mg Tablets.

This "Changes Being Effected" supplemental new drug application provides for final printed labeling revised as follows:

1. The word, "anaphylaxis" has been added to the ADVERSE REACTIONS/Body as a whole subsection.
2. Under the HOW SUPPLIED section, the National Stock Numbers have been deleted and the corporate logo and signature have been updated.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the final printed label included in your September 19, 2001 submission. Accordingly, the supplemental application is approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:


MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Ms. Zelda McDonald
Regulatory Health Project Manager
(301) 594-5333

Sincerely,

{See appendix  electronic signature page}

Douglas C. Throckmorton, M.D.
Acting Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Doug Throckmorton
3/27/02 03:24:20 PM

RHPM Review of Final Printed Labeling
NDA 18-017/S-037

Date of Submission: September 19, 2001
Date of Review: March 14, 2002
Applicant Name: Merck
Product Name: Blocadren (timolol maleate) 5, 10 and 20 mg Tablets

Evaluation:

This is a Special Supplement- Changes Being Effected that provides for electronic final printed labeling revised as follows:

1. The word, "anaphylaxis" has been added to the ADVERSE REACTIONS/Body as a whole subsection.
2. Under the HOW SUPPLIED section, the National Stock Numbers have been deleted and the corporate logo and signature have been updated.

There were no other changes from the last approved package insert

Recommendation:

An approval letter should issue for this supplement as set forth under 21 CFR 314.70 (c) (i) [To add or strengthen a contraindication, warning, precaution, or adverse reaction].


/S/

Zelda McDonald
Regulatory Health Project Manager

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Zelda McDonald
3/28/02 01:12:46 PM
CSO



Shari L. Targum, M.D.
Division of Cardio-Renal Drug Products, HFD-110
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20816
Tel (301) 594-5384, FAX (301) 594-5494

Memorandum

DATE: March 25, 2002
FROM: Shari L. Targum, M.D.
TO: #18,017
SUBJECT: Supplement #S-037

Correspondence Date: September 19, 2001
Date Assigned: September 21, 2001
Date Completed: February 25, 2002
Drug: Blocadren® (timolol maleate)
Sponsor: Merck & Co., Inc.

The sponsor submitted a labeling supplement for Blocadren® (timolol maleate). This product is currently approved for hypertension, myocardial infarction, and migraine. The usual initial dosage for hypertension and migraine is 10 mg twice daily; the recommended dosage in myocardial infarction is also 10 mg twice daily.

Under ADVERSE REACTIONS, *Body as a Whole*, anaphylaxis has been added, based on WAES case reports.

Under Precautions, a paragraph entitled "*Risk of Anaphylactic Reaction*" exists in the current labeling.

According to Michael Johnston (Safety Evaluator, ODS/DDRE, HFD-430), there are six cases of anaphylaxis associated with timolol in their database.

Comment: The proposed labeling change is acceptable to this reviewer.

c.c.: NDA #18-017
HFD-110
HFD-110/McDonald
HFD-110/Stockbridge

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Shari Targum
3/25/02 11:28:00 AM
MEDICAL OFFICER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-017/S-037

Merck & Co., Inc.
Attention: Mr. Kenneth A. Kramer
Sumneytown Pike
P.O. 4, BLA-20
West Point, PA 19486

Dear Mr. Kramer:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Blocadren (timolol maleate) Tablets

NDA Number: 18-017

Supplement number: S-037

Date of supplement: September 19, 2001

Date of receipt: September 20, 2001

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on November 19, 2001 in accordance with 21 CFR 314.101(a).

All communications concerning this supplement should be addressed as follows:

U.S. Postal Service:

Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Attention: Division Document Room
5600 Fishers Lane
Rockville, Maryland 20857

Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Attention: Division Document Room
1451 Rockville Pike
Rockville, Maryland 20852

If you have any questions, please call:

Ms. Colleen LoCicero
Regulatory Project Manager
(301) 594-5332

Sincerely yours,

A stylized handwritten signature consisting of a large, bold letter 'S' with a diagonal slash through it, positioned between two short horizontal lines.

Natalia A. Morgenstern
Chief, Project Management Staff
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Natalia Morgenstern
9/25/01 05:40:42 PM